IKA: Initial Stereax revenues and strong grant funding support growth despite widened EBITDA loss
Key milestones achieved in Stereax and Goliath product lines, with initial commercial revenues and strong grant funding. EBITDA loss widened to £6.2m, but cash resources and new share placing support ongoing growth and commercialisation.Original document: Ilika plc [IKA] Slides Release — Jul. 29 20…